New Cabotegravir Data at IDWeek 2026

By Meaghan Lee Callaghan and Landon GrayNew research on the real-world use of cabotegravir for pre-exposure prophylaxis (Apretude, ViiV Healthcare) and also data on cabotegravir/rilpivirine (Cabenuva, ViiV Healthcare) has been presented at IDWeek 2026, in Washington, D.C. The data, now spanning out to 5 years, shows good results for people who want to prevent HIV infection or want to keep their infections down to undetectable levels.ViiV’s CMO Jean Van Wyk, MBChB, MFPM, sat down with Infectio